Prise en charge médicale du Covid-19, hors réanimation
MEDICAL MANAGEMENT OF COVID-19, EXCLUDING INTENSIVE CARE Management of Covid-19 is primarily guided by the severity of the respiratory involvement. Covid-19 is mostly asymptomatic or pauci-symptomatic allowing the ambulatory setting associated with isolation measures going from 5 to 10 days depending on the circumstances. Nirmatrelvir/ritonavir (Paxlovid) is currently the oral treatment for Covid-19 in adult patients not requiring oxygen therapy and at risk of severe disease in the absence of contraindications. For hospitalized patients requiring oxygen support, corticosteroid therapy and anticoagulation are the main supportive treatments in association with measures preventing secondary cases. The antiviral approach is limited in this context, consisting in passive immunotherapy (mostly neutralizing monoclonal antibodies) or direct-acting antivirals active on the dominant variant and that have demonstrated clinical efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
La Revue du praticien - 72(2022), 5 vom: 06. Mai, Seite 505-510 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Medical management of covid-19, excluding intensive care |
|---|
| Beteiligte Personen: |
Javaux, Clément [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 29.07.2022 Date Revised 29.07.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM344193799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344193799 | ||
| 003 | DE-627 | ||
| 005 | 20231226022210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344193799 | ||
| 035 | |a (NLM)35899636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Javaux, Clément |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prise en charge médicale du Covid-19, hors réanimation |
| 246 | 3 | 3 | |a Medical management of covid-19, excluding intensive care |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.07.2022 | ||
| 500 | |a Date Revised 29.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a MEDICAL MANAGEMENT OF COVID-19, EXCLUDING INTENSIVE CARE Management of Covid-19 is primarily guided by the severity of the respiratory involvement. Covid-19 is mostly asymptomatic or pauci-symptomatic allowing the ambulatory setting associated with isolation measures going from 5 to 10 days depending on the circumstances. Nirmatrelvir/ritonavir (Paxlovid) is currently the oral treatment for Covid-19 in adult patients not requiring oxygen therapy and at risk of severe disease in the absence of contraindications. For hospitalized patients requiring oxygen support, corticosteroid therapy and anticoagulation are the main supportive treatments in association with measures preventing secondary cases. The antiviral approach is limited in this context, consisting in passive immunotherapy (mostly neutralizing monoclonal antibodies) or direct-acting antivirals active on the dominant variant and that have demonstrated clinical efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibodies, Monoclonal | |
| 650 | 4 | |a Antiviral Agents | |
| 650 | 4 | |a Covid-19 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Ader, Florence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue du praticien |d 1951 |g 72(2022), 5 vom: 06. Mai, Seite 505-510 |w (DE-627)NLM000023248 |x 2101-017X |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2022 |g number:5 |g day:06 |g month:05 |g pages:505-510 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2022 |e 5 |b 06 |c 05 |h 505-510 | ||